On May 2nd 2022, CSI made its largest acquisition in history acquiring Allscripts’ Hospital EHR business for $725m. The transaction was financed with ~50/50 debt and equity, making Allscripts the second LBO conducted internally at CSI after Acceo in 2018.
As we’ve previously discussed, increased competition and the law of large numbers is pushing CSI into acquiring larger assets. In 2023 YTD, CSI has deployed a record $1.9bn into acquisitions, with $1.4bn into assets with an enterprise value over $200m. This includes Orbis Blue for $700m, Wide Orbit for $500m, and $200m for Empower.
We’ve spent 6+ hours interviewing Former Allscripts and Altera executives to understand drivers of Altera’s Y1 performance and the long-run opportunity in larger acquisitions.
In its first year of ownership, CSI has generated $104m in FCF at Altera, a Y1 ROE of 26.5%. However, our primary research suggests there are two fundamental reasons why Altera’s 10-year IRR may hit the lower-end of forecasts:
Higher than expected customer churn
CSI’s operational playbook less effective than usual
This analysis shares our learnings and explores Altera’s challenges in more detail.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities.
© 2023 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research